Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2023-03-15 Proxy Solicitation & In…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Vivozon Pharmaceutical. It outlines the date, location, and specific agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits) to be voted on at the upcoming meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of the meeting and the matters to be decided.
2023-03-15 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Vivozon Pharmaceutical. It contains the meeting agenda, details on voting procedures, electronic voting instructions, and financial statements (balance sheet, income statement, etc.) as part of the meeting materials. According to the filing definitions, documents detailing materials shared for an AGM are classified as 'AGM-R'.
2023-03-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details changes in share ownership by Synergy IB Investment and its special related parties in the company Bibo-Zone Pharmaceutical. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-03-10 Korean
[기재정정]투자판단관련주요경영사항(오피란제린 주사제 한국 임상3상 Topline 결과 발표)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean pharmaceutical company (Vivozon Pharmaceutical) regarding the results of a Phase 3 clinical trial for a drug called 'Opiranzerin'. It is structured as a 'Major Management Matter' (주요경영사항) filing, which is a standard regulatory disclosure format in Korea for reporting material events such as clinical trial outcomes. It provides detailed statistical data on primary and secondary endpoints, safety results, and conclusions, rather than just announcing the existence of a report. Therefore, it is classified as a Regulatory Filing (RNS).
2023-03-06 Korean
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Vivozon Pharmaceutical. It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2023-02-28 Korean
[기재정정]전환청구권행사(제19회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (전환사채). It details the number of shares issued, the conversion price, and the remaining balance of the convertible bonds. This type of corporate action, involving changes to share capital structure through the conversion of debt into equity, falls under the 'Share Issue/Capital Change' category.
2023-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.